Fig. 6

EDO-S101 synergizes with bortezomib in in vitro and in vivo experiments, by potentiating acetylation and DNA damage. a MM1S cells were treated with suboptimal concentrations of EDO-S101 and other drugs with anti-myeloma effect for 48 h. b Western blot evaluation of the indicated proteins after treatment with bortezomib 3 nM and EDO-S101 2 μM, alone, and in combination for 48 h. c Mice bearing a subcutaneous plasmacytoma of MM1S cells were randomized to receive vehicle (control), EDO-S101 (30 mg/kg, iv, weekly), bortezomib (1.25 mg/kg, 2 days per week), and bortezomib + EDO-S101. Differences in tumor growth inhibition were statically significant between the bortezomib + EDO-S101 group and the rest of groups from day 16 (p < 0.05). d The graphic shows a Kaplan–Meier evaluation of the survival of mice treated as in c. (asterisk indicates statistical significance. Log Rank p < 0.005)